Table 1 Baseline patients’ characteristics
From: Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
|  | Total cohort (n = 32) | Treatment failure (n = 11) | Treatment success (n = 21) | p value |
|---|---|---|---|---|
Demographics and comorbidities | ||||
 Age, years | 56 [46–68.5] | 55 [49.75–71] | 56 [45–68.25] | 0.75 |
 Male sex, N (%) | 17 (53.1) | 5 (45.5) | 12 (57.1) | 0.8 |
 Weight, (kg) | 76.5 [60–90] | 75 [67.8–80] | 90 [60–100] | 0.45 |
 Albumin, (g/dL)* | 23 [21.5–26.5] | 22 [19.25–26.25] | 24 [22.75–26.5] | 0.17 |
 Fluid balance, (mL)* | +762.9 [−393 to +3703.5] | +3332 [−1124.2 to + 4112] | 616.3 [−358.5 to  + 2592.7] | 0.5 |
 SAPS II score | 53.5 [44.5–67.5] | 61 [44.7–66.5] | 52 [43.5–67.5] | 0.92 |
 Cardiovascular diseases, N (%) | 6 (18.75) | 3 (27.3) | 3 (14.3) | 0.39 |
 COPD, N (%) | 5 (15.6) | 1 (9.1) | 4 (19.1) | 0.64 |
 Chronic renal failure, N (%) | 7 (21.9) | 3 (27.3) | 4 (19.1) | 0.4 |
 Diabetes, N (%) | 3 (9.4) | 0 | 3 (14.3) | 0.53 |
 Neoplasm, N (%) | 7 (21.9) | 4 (36.4) | 3 (14.3) | 0.2 |
Presenting features and outcomes | ||||
 ICU LOS before TGC, (days) | 7.5 [2.5–16] | 5 [0.5–11.25] | 12 [3.75–18.25] | 0.13 |
 MV duration before TGC (days) | 8 [3–12] | 5 [0.5–11.25] | 8 [3.75–14.75] | 0.19 |
 Vasopressors duration before TGC (days) | 4.5 [0–8.5] | 5 [0.25–8.25] | 4 [0–8.25] | 0.89 |
 SOFA score* | 7 [4–10] | 8 [4.75–12] | 6 [4–9] | 0.2 |
 Septic shock, N (%)* | 18 (56.3) | 7 (63.6) | 11 (52.4) | 0.71 |
 ARF requiring MV, N (%)* | 28 (87.5) | 10 (90.9) | 18 (85.7) | 1 |
 AKI requiring CRRT, N (%)* | 11 (34.4) | 3 (27.3) | 8 (38.1) | 0.7 |
 Creatinine clearance (ml/min)* | 97.3 [32–150.8] | 63.2 [32–155] | 104 [30–142] | 0.85 |
 VAP, N (%) | 19 (59.4) | 3 (27.3) | 16 (76.2) | 0.02 |
Non-pulmonary infections, N (%)# | 13 (40.6) | 8 (72.7) | 5 (23.8) | 0.02 |
 Secondary bacteraemia, N (%) | 13 (40.6) | 4 (36.4) | 9 (42.9) | 1 |
 Source control, N (%) | 13 (40.6) | 7 (63.6) | 6 (28.6) | 0.07 |
 TGC therapy duration,(days) | 12 [9–15] | 12 [10–15] | 11 [8–17] | 0.69 |
 TGC empirical therapy, N (%) | 17 (53.1) | 7 (63.6) | 10 (47.6) | 0.47 |
 Gram-positive bacteria N (%)** | 11 (34.4) | 4 (36.4) | 7 (33.3) | 1 |
 Gram-negative bacteria N (%)*** | 29 (90.6) | 10 (90.9) | 19 (90.5) | 1 |
 ICU LOS after TGC, (days) | 15 [10.5–27] | 14.5 [12–19] | 16 [10–31.4] | 0.42 |
 MV duration after TGC (days) | 10 [5–15] | 14 [9.75–15.75] | 8 [2–13.5] | 0.04 |
 Vasopressors duration after TGC (days) | 3 [1.5–13] | 8 [2.25–13] | 3 [0–10.75] | 0.12 |
 30-day mortality | 9 (28.1) | 8 (72.7) | 1 (4.8) | < 0.001 |